Myopathy Associated with Treatment of Graves' Disease

Medicina (Kaunas). 2021 Sep 25;57(10):1016. doi: 10.3390/medicina57101016.

Abstract

Here, we report a case of an increase in serum creatine kinase (CK) concentration in an 11-year-old girl being treated for Graves' disease with antithyroid drugs (ATDs). The patient complained of myalgia two weeks after methimazole treatment. Triiodothyronine (T3) and free thyroxine (FT4) levels were normal, but the serum CK level was significantly elevated. After switching to propylthiouracil, the serum CK level decreased to normal, and the myalgia was resolved. The development of myopathy during the treatment of hyperthyroidism may be considered as an adverse reaction of MMI. In this report, we present a rare pediatric case, along with a discussion on the possible causes of myopathy that occurred during the treatment of Graves' disease. A careful follow-up (serum CK levels and thyroid function) and treatment reassessment should always be considered after antithyroid treatment.

Keywords: creatine kinase; graves’ disease; methimazole; myopathy.

Publication types

  • Case Reports

MeSH terms

  • Antithyroid Agents / adverse effects
  • Child
  • Female
  • Graves Disease* / complications
  • Graves Disease* / drug therapy
  • Humans
  • Methimazole / adverse effects
  • Myalgia
  • Thyroxine*
  • Triiodothyronine

Substances

  • Antithyroid Agents
  • Triiodothyronine
  • Methimazole
  • Thyroxine